199 results
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
Nominees possess these qualities: Strategic Thinking Sound Business Judgment Integrity & Ethics Leadership
9 Continued Commitment to our Compensation
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
18 Mar 24
Strengthening Neuroscience Portfolio
8:56am
Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “Importantly, this transaction aligns with our commitment to strengthening BMS’s growth … continued commitment to strong investment-grade credit ratings and investment for growth through business development opportunities and distributions
8-K
EX-99.2
itjnibnat5jra s3gh
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
SC TO-T
EX-99
wr83m euwp9gp74
25 Jan 24
Third party tender offer statement
8:13am
8-K
EX-99.1
4q3ema
8 Jan 24
Regulation FD Disclosure
10:29am
SC TO-C
EX-99.1
zsg7wf3
26 Dec 23
Information about tender offer
4:22pm
DFAN14A
EX-99.1
eyr3uvc23040d3
22 Dec 23
Additional proxy materials by non-management
4:21pm
8-K
EX-99.1
oi85bej
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
8-K
EX-99.1
q6y6hzecz
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
DFAN14A
wkg0pv7es77p5l7gdl
10 Oct 23
Additional proxy materials by non-management
6:48am
DEFA14A
g48c4n410r5ol9ep
26 Apr 23
Additional proxy soliciting materials
4:38pm
8-K
EX-99.1
8wigupr
26 Apr 23
Bristol Myers Squibb Announces Leadership Transition Plan
4:35pm
DEFA14A
ovghyn
10 Apr 23
Additional proxy soliciting materials
5:12pm
SC TO-T
EX-99
goa4l
17 Jun 22
Third party tender offer statement
4:42pm
8-K
EX-99.3
xdzxjwig q5
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
8-K
EX-99.1
iaij0rr
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
DEFA14A
g4h1j4 rf
20 Apr 22
Additional proxy soliciting materials
4:30pm